celecoxib has been researched along with Cardiovascular Abnormalities in 1 studies
Cardiovascular Abnormalities: Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, L | 1 |
| Thorn, CF | 1 |
| Bertagnolli, MM | 1 |
| Grosser, T | 1 |
| Altman, RB | 1 |
| Klein, TE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Control Trial Study of the Efficacy of Celecoxib Versus Ketorolac for Perioperative Pain Control[NCT03331315] | Phase 2 | 170 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average inpatient hydromorphone use measured in milligrams (NCT03331315)
Timeframe: 48 hrs following surgery
| Intervention | Milligrams (Mean) |
|---|---|
| Ketorolac | 0.7 |
| Celecoxib | 0.8 |
Average inpatient ondansetron use measured in milligrams (NCT03331315)
Timeframe: 48 hrs following surgery
| Intervention | Milligrams (Mean) |
|---|---|
| Ketorolac | 1.5 |
| Celecoxib | 1.3 |
Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff. (NCT03331315)
Timeframe: 48 hrs following surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Ketorolac | 2.7 |
| Celecoxib | 2.4 |
Measured using postoperative questionnaire (NCT03331315)
Timeframe: 2 weeks after discharge
| Intervention | Days (Mean) |
|---|---|
| Ketorolac | 5.7 |
| Celecoxib | 3.8 |
Number of oral narcotic pills used after discharge until 2 week postoperative visit. (NCT03331315)
Timeframe: 2 weeks after discharge
| Intervention | Pills (Mean) |
|---|---|
| Ketorolac | 8.1 |
| Celecoxib | 6.0 |
Perioperative Complications measured intraoperatively and postoperatively by type (NCT03331315)
Timeframe: During and after surgery
| Intervention | Patients (Number) |
|---|---|
| Ketorolac | 5 |
| Celecoxib | 6 |
Average number of days required for complete return to independent activities of daily living (NCT03331315)
Timeframe: 2 weeks after discharge
| Intervention | Days (Mean) |
|---|---|
| Ketorolac | 2.4 |
| Celecoxib | 2.2 |
Total hospital stay from time fo admission to time of discharge measured in hours (NCT03331315)
Timeframe: Following surgery
| Intervention | Hours (Mean) |
|---|---|
| Ketorolac | 11.6 |
| Celecoxib | 11.9 |
1 other study available for celecoxib and Cardiovascular Abnormalities
| Article | Year |
|---|---|
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |